Skip to main content
. Author manuscript; available in PMC: 2020 Oct 28.
Published in final edited form as: Clin Genitourin Cancer. 2016 Sep 8;15(2):326–335.e3. doi: 10.1016/j.clgc.2016.08.020

Table 3.

Patient toxicity, stratified by T2DM group.

T2DM group RTOG toxicity, grade 2-4
Early, incidence GU GI
N % % n p-val % n p-val
I No T2DM 2603 81 26 688 Ref 5 146 Ref
II Metformin 251 7.8 28 76 0.19 7 18 0.31
III Non-metformin oral antihyperglycemic 148 4.6 21 32 0.20 4 6 0.42
IV Any insulin 89 2.8 38 34 0.01 12 11 0.01
V T2DM, no meds 126 3.9 22 28 0.29 9 11 0.14
 
Late, KM at 3 years
N % % 95% CI p-val % 95% CI p-val
I No T2DM 2603 81 2.5 1.9 3.3 Ref 5.9 5.0 7.0 Ref
II Metformin 251 7.8 2.1 0.8 5.6 0.25 6.1 3.5 10.5 0.42
III Non-metformin oral antihyperglycemic 148 4.6 4.8 2.2 10.4 0.18 7.8 4.2 14.0 0.49
IV Any insulin 89 2.8 11.4 5.5 22.6 0.001 13.7 7.6 24.1 0.01
V T2DM, no meds 126 3.9 11.9 6.3 21.9 0.001 13.9 8.4 22.5 0.001

Abbreviations: CI: confidence interval; KM: Kaplan-Meier; RTOG: Radiation Therapy Oncology Group; sHR: sub hazard ratio